{
    "root": "a006cd62-d3e9-4ded-b472-36b918746bac",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clobazam",
    "value": "20250206",
    "ingredients": [
        {
            "name": "CLOBAZAM",
            "code": "2MRO291B4U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31413"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        }
    ],
    "indications": {
        "text": "clobazam tablets benzodiazepine indicated adjunctive treatment seizures associated lennox-gastaut syndrome ( lgs ) patients 2 years age older ( 1 )",
        "doid_entities": [
            {
                "text": "lennox-gastaut syndrome (DOID:0050561)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050561"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "lennox-gastaut syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_2382"
            }
        ]
    },
    "contraindications": {
        "text": "doses 5 mg/day administer two divided doses ( 2.1 ) patients \u226430 kg body weight : initiate 5 mg daily titrate tolerated 20 mg daily ( 2.1 ) patients > 30 kg body weight : initiate 10 mg daily titrate tolerated 40 mg daily ( 2.1 ) adjustment needed following groups : geriatric patients ( 2.4 , 8.5 ) known cyp2c19 poor metabolizers ( 2.5 ) mild moderate hepatic impairment ; information severe hepatic impairment ( 2.7 , 8.8 ) tablets : administer whole , broken half along score , crush mix applesauce ( 2.3 ) tablets : taken without food ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "clobazam tablets , 10 mg : white off-white , oval tablets functional score one side ' l ' ' 7'debossed either side scoreline plain side . clobazam tablets , 20 mg : white off-white , oval tablets functional score one side ' l ' ' 8'debossed either side scoreline plain side . ndc 68180-157-01 : 10 mg scored tablet , bottles 100 ndc 68180-158-01 : 20 mg scored tablet , bottles 100 store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) [ usp controlled room temperature ] .",
    "adverseReactions": "history hypersensitivity ingredients ( 4 )",
    "indications_original": "Clobazam tablets are a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older ( 1 )",
    "contraindications_original": "For doses above 5 mg/day administer in two divided doses ( 2.1 ) Patients \u226430 kg body weight: Initiate at 5 mg daily      and titrate as tolerated up to 20 mg daily ( 2.1 ) Patients >30 kg body weight: Initiate at 10 mg daily      and titrate as tolerated up to 40 mg daily ( 2.1 ) Dosage adjustment needed in following groups: Geriatric patients ( 2.4 , 8.5 ) Known CYP2C19 poor metabolizers ( 2.5 ) Mild or moderate hepatic impairment; no information for      severe hepatic impairment ( 2.7 , 8.8 ) Tablets: Administer whole, broken in half along the score,      or crush and mix in applesauce ( 2.3 ) Tablets: Can be taken with or without food ( 2.3 )",
    "warningsAndPrecautions_original": "Clobazam tablets, 10 mg: White to off-white , oval tablets with functional score on one side with 'L' and '7'debossed either side of scoreline and plain on other side.\n                  Clobazam tablets, 20 mg: White to off-white, oval tablets with functional score on one side with 'L' and '8'debossed either side of scoreline and plain on other side.\n                  NDC 68180-157-01: 10 mg scored tablet, Bottles of 100 \n                  NDC 68180-158-01: 20 mg scored tablet, Bottles of 100 \n                  Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "History of hypersensitivity to the drug or its ingredients ( 4 )",
    "drug": [
        {
            "name": "Clobazam",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31413"
        }
    ]
}